Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 5Unknown 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Prostatic Neoplasms 594Carcinoma, Renal Cell 276Urinary Bladder Neoplasms 175Kidney Neoplasms 112Neoplasms 101Neoplasm Metastasis 94Carcinoma, Non-Small-Cell Lung 94Carcinoma, Transitional Cell 86Melanoma 85Breast Neoplasms 83Ovarian Neoplasms 64Lung Neoplasms 50Colorectal Neoplasms 50Pancreatic Neoplasms 43Stomach Neoplasms 40Sarcoma 37Squamous Cell Carcinoma of Head and Neck 35Triple Negative Breast Neoplasms 31Testicular Neoplasms 29Uterine Cervical Neoplasms 27Esophageal Neoplasms 26Carcinoma, Hepatocellular 26Head and Neck Neoplasms 24Non-Muscle Invasive Bladder Neoplasms 23Small Cell Lung Carcinoma 22Colonic Neoplasms 20Urologic Neoplasms 17Neuroblastoma 17Multiple Myeloma 17Endometrial Neoplasms 17

Interventions

enzalutamide 1apalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Patient Preference × Genitourinary × Clear all
NCT04409288 2024-01-05

Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer

Chinese University of Hong Kong

Phase 3 Terminated
74 enrolled
Genitourinary

Prostatic Neoplasms, Patient Preference

Data powered by HemOnc (CC BY 4.0) Colophon âš¡